What is the prevalence of leiomyosarcomas and atypical leiomyomas after laparoscopic morcellation of fibroids in reproductive age women?
Introduction
The majority of female genital tract neoplasms arise from uterine smooth muscle. Based upon microscopic morphologic features, such as coagulative tumor necrosis, atypical cytology, cellularity and mitotic index, these tumors are categorized as benign leiomyomas, benign variants of leiomyomas (mitotically active leiomyoma, cellular leiomyoma and atypical-bizarre leiomyoma), smooth muscle tumor of uncertain malignant potential (STUMP), leiomyosarcoma, endometrial stromal sarcoma, undifferentiated uterine sarcoma (Ip and Cheung, 2011) .
Benign leiomyomas known as uterine fibroids represent the most common gynecological neoplasm and the estimated life-time risk of uterine leiomyoma by age 50 years is 70% in white women and 80% in black women (Baird et al., 2003) . In reproductive age women, 15-30% of these tumors are responsible for menstrual disorders, anemia due to profuse uterine bleeding, pelvic pain, pregnancy loss, rarely preterm delivery and infertility (Bulun, 2013) . Thus, fibroids are an important public health issue, because a large number of women are affected by them and when symptomatic fibroids require treatment by open myomectomy or hysterectomy, the cost is extremely high for the health system because the procedure is associated with higher morbidity rates, longer hospitalization and longer return to normal activities than vaginal or laparoscopic procedures (AAGL, 2014) .
According to a recently published randomized trial, in reproductive age women who wish to preserve their fertility, laparoscopic myomectomy compared to laparotomy, has been established as the gold standard surgical intervention in the treatment of uterine fibroids. Laparoscopic versus open myomectomy is associated with less postoperative morbidity and shorter hospital stays, but with no significant difference regarding reproductive and obstetric outcomes between the two surgical approaches. (Chittawar et al., 2014) .
Recently, laparoscopic myomectomy has become an issue of debate, as the Food and Drug Administration (FDA) released a warning (initially in April 2014 but updated in November 2014), against the use of laparoscopic power morcellators to remove presumed benign uterine fibroids in small fragments through laparoscopic incisions. This recommendation was based on the potential risk of intra-peritoneal dissemination of unsuspected uterine sarcoma during morcellation, which may decrease the long-term survival of these women. The FDA estimated prevalence of unsuspected sarcoma after primary analysis of nine out of 18 identified studies in the literature, was one case of unsuspected uterine sarcoma in 352 women and one case of unsuspected leiomyosarcoma in 458 women undergoing hysterectomy or myomectomy for presumed benign leiomyoma (FDA, 2014a,b) .
Although uterine sarcoma is a rare entity affecting usually older perior post-menopausal women, there are limited and poor quality epidemiologic data regarding its prevalence in reproductive age women planning surgery for presumed benign leiomyomas. The largest series of uterine sarcomas included 2677 cases with mean age at the time of diagnosis, 64.2 years in white women and 62.7 years in black women. The adjusted prevalence in black women was nearly 2-fold greater than of white women (0.007% or 1 in 14 286 versus 0.0036% or 1 in 27 778) (Brooks et al., 2004) .
The lack of sufficient evidence in the literature, encouraged us to perform this retrospective study, to identify the prevalence of occult uterine sarcomas and benign atypical leiomyomas in our population after laparoscopic morcellation of presumed benign fibromas in reproductive age women.
Materials and Methods
In this retrospective study, the medical records of all consecutive women, who underwent laparoscopic myomectomy with morcellation of the surgical specimens were reviewed in order to identify the incidence of atypical leiomyomas and sarcomas.
This study was conducted in the gynecological endoscopic unit of 'Diavalkaniko' hospital, Thessaloniki, Greece, between June 2003 and December 2015. Due to the retrospective nature of the study and because the data retrieved were anonymous no approval by the Ethics Committee was obtained and no woman gave her informed consent within the scope of this retrospective analysis. During the above period, all operations were performed by the same gynecologist (G.P.) and assisted by one of the other authors.
Indications for intervention were: (i) symptomatic growth of a known uterine leiomyoma (when the patient reported changes in the menstrual profile (menometrorrhagia) or the size of the leiomyoma increased by at least 30% within a 3-month period). (ii) Infertility if distortion of the uterine cavity was revealed by hysterosalpingography. (iii) History of abortion or preterm delivery if the presence of the leiomyoma compromised the shape of the uterine cavity. (iv) Chronic pelvic pain due to degeneration of the leiomyoma.
All patients were preoperatively examined by the same gynecologist (G.P.) in our outpatient department and were diagnosed with presumed benign leiomyoma based on defined ultrasonographic criteria (Exacoustos et al., 2007) , although there are no pathognomonic sonographic features to distinguish a uterine leiomyosarcoma from leiomyoma. According to these a benign leiomyoma is usually a round shaped lesion <8 cm in diameter a with regular outline and absence or limited growth over several months of follow-up. The echogenicity ranged from uniform hypoechogenic or hyperechogenic to lesions of mixed echogenicity with the presence of calcifications with shadowing. The addition of color Doppler flow to grey scale sonography allows the assessment of vascularity of leiomyoma, which is mainly peripheral or absent with mild or moderate blood flow. In suspicious solitary and large lesions with central necrosis or high blood flow with irregular branching vessels, during the preoperative sonographic work up, gadolinium enhanced MRI was used to further evaluate the tissue characteristics of the lesions and exclude malignancy. Our preoperative selection was based on the above mentioned criteria and a uterine lesion was considered arbitrarily benign if four or more of Exacoustos' criteria were fulfilled. In cases with suspicious ultrasound and MRI features, laparotomy was suggested instead of laparoscopy.
During the preoperative work-up, an abnormal normal pap smear, sonographic focal or diffuse thickness or breakage of endometrial lining, were indications for colposcopy and diagnostic hysteroscopy or curettage before laparoscopic myomectomy in order to exclude any pre-invasive or invasive cervical or uterine cancer. Any of these findings were considered contraindications for laparoscopic myomectomy. Also, there were no patients in the study group with history of hereditary leiomyomatosis or who had received tamoxifen or pelvic irradiation in the past.
All specimen slides were examined by the same experienced pathologist (T.Z.) after hematoxylin-eosin staining. As benign leiomyomas were defined uterine lesions consisting of smooth muscle cells without atypia, absence of necrosis and mitotic index (MI) < 5 per 10 high power field (HPF). Although leiomyomas grow slowly, they may undergo secondary changes such as hyaline, cystic or myxoid changes as well as red degeneration. They may appear as benign variants of leiomyoma due to the presence of atypical histological features such as high MI (>5) or the presence of atypical-bizarre giant cells, but with no other worrisome features fulfilling the Stanford criteria for leiomyosarcoma. (Bell et al., 1994) . These variants of leiomyoma are regarded as 'mitotically active' leiomyoma or leiomyoma with atypical-bizarre nuclei. Another benign appearing uterine smooth muscle tumor containing only tumor cell necrosis, without significant atypia and MI≤10 may occasionally exhibit potential malignancy is considered as STUMP.
Statistical analysis
The results were entered in Microsoft Excel and the data were analyzed with SPSS statistics 19 software. The Kruskal-Wallis test was used to compare differences between benign and atypical leiomyomas and descriptive statistics to present population characteristics. The mean values and standard deviations for various parameters were calculated. P < 0.05 was considered to indicate statistical significance.
Results
The indications for laparoscopic myomectomy were abnormal menstrual bleeding in 892 (73.3%) patients, symptomatic rapid growth of leiomyomas in reproductive age women in 132 (10.8%) patients, infertility in 163 (13.4%) patients, abortion and/or preterm delivery in 25 (2.05%) patients and chronic pelvic pain in 4 (0.32%) patients. No case of leiomyosarcoma 0% (95% CI: 0-0.3%) was identified among the 2582 myomas that were removed from 1216 women. The mean (±SD) age of the patients was 36.4 ± 5.2 and 34.0 ± 5.02 y in women with normalbenign and atypical-bizarre leiomyomas, respectively (P = NS). The location and the orientation of 2582 operated leiomyomas of 1216 patients are described in Table I including six patients with atypical-bizarre and one with mitotically active leiomyoma. The mean (±SD) diameter was 4.27 ± 2.44 and 5.33 ± 0.81 cm in benign and atypical-bizarre leiomyomas, respectively. The term 'insufficient data' refers to the location and orientation respectively of the smaller leiomyomas in cases of women with multiple ones. Thirty four cases of leiomyomas were characterized as adenomyomas, 45 as leiomyomas with infarcts, 81 as cellular myomas and 133 as degenerated (Table II) .
In all 1216 patients who underwent laparoscopy for presumed benign leiomyomas according to our preoperative selection criteria, six atypical-bizarre and one mitotically active leiomyomas were found (0.6% 95% CI: 0.23-1.18%). The pathologic and ultrasonographic findings of the six cases of atypical-bizarre and one case of mitotically active leiomyomas are presented in Table III . We excluded from our study population 22 cases with suspicious MRI and sonographic features. Eighteen of them were operated by laparotomy and no case of leiomyosarcoma was diagnosed in the pathology specimen, while the other four patients were lost to follow-up. No morcellator-associated complication was noticed and none of the patients included in this study required conversion to laparotomy.
In all seven patients with atypical myomas (six atypical-bizarre and one mitotically active) the diagnosis was established by final histopathologic examination of the removed specimen in pieces with the use of electromechanical morcellation. The histopathological details of the atypical leiomyomas are shown in Table II .
Discussion
Laparoscopic myomectomy is one of the most common indication for tissue morcellation. However, the use of electromechanical morcellators is associated with three severe risks. First, direct injuries to the adjacent organs. Second, spread of benign leiomyomatous tissue giving rise to parasitic leiomyomas necessitating further surgical reexploration. Third possible intra-peritoneal spilling of occult cancerous uterine tissue with its adverse effects on patient's survival outcome. (Park et al., 2011a,b; George et al., 2014) .
The debate about the use or not of power morcellators in laparoscopic myomectomy began even before the FDA warning, because of the lack of clear clinical features and reliable preoperative diagnostic tools to distinguish benign leiomyomas from sarcomas, but it was the FDA warning which altered substantially the everyday clinical practice not only in USA, but, also in Europe. So, in a recent Italian survey on the impact of FDA safety communication on the use of power morcellation, 58.7% of gynecologists declared that they would change their surgical approach to prevent legal litigation. (Mandato et al., 2016) .
Because of the absence of an accurate diagnostic preoperative or intra-operative modality to differentiate a benign leiomyoma from a uterine sarcoma, all patients with presumed benign leiomyomas should be considered at a rare risk to be finally diagnosed with an unsuspected uterine sarcoma. It is obvious that we have to standardize our clinical management by the adoption of a flowchart in order to classify patients based on the possible risk of a sarcoma in a presumed benign leiomyoma (Brolmann et al., 2015) . According to a recently published meta-analysis of 64 prospective studies encompassing 5223 women with presumed benign leiomyomas, the prevalence of occult leiomyosarcoma was 1 per 8300 procedures. This rate is significantly lower compared to the incidence of 1 leiomyosarcoma per 1700 surgeries in 70 retrospective case series including 24 970 patients. (Pritts et al., 2015) . Both estimated rates reported in this recent systematic review and comprehensive analysis are substantially lower than those previously reported after FDA analysis encompassing only nine out of the 18 identified studies. Possible explanation of this discrepancy is that FDA reviewers included in their analysis only papers using the search terms 'uterine cancer' as a required search term excluding those studies without occult uterine cancers after laparoscopic morcellation of presumed benign leiomyomas. Furthermore, FDA reviewers included studies with a size above an arbitrary limit of 100 patients excluding studies with small patient populations. Most of the studies included in the analysis included patients who underwent both hysterectomy and myomectomy without stratification by procedure or age. It is known that hysterectomy is usually performed on older age women with large suspicious uterine lesions and their risk of sarcoma is higher than in younger women who undergo myomectomy. Nevertheless the true prevalence of sarcoma in reproductive age women is not known because of selection bias in the low quality trials available.
Interestingly, a recent retrospective study, which included 8720 out of 10731 morcellated uteri with the indication of uterine myomas, found that the prevalence of occult sarcomas was as low as 0.05% and the mean (±SD) age was 50.2 (±5.8) years without any woman younger than 45 years old diagnosed with leiomyosarcoma (Bojahr et al., 2015) . The results of this study are indicative of the extremely low prevalence of leiomyosarcoma in young women undergoing myomectomy compared to older ones who have undergone hysterectomy.
The 0% incidence of leiomyosarcoma in our study is supported by the results from another retrospective study including 4791 women operated for uterine myomas. Among them, 1846 underwent 1957 laparoscopic procedures (laparoscopic total or supracervical hysterectomy and laparoscopic myomectomy) and 26 cases of leiomyosarcomas were diagnosed. Only one case was laparoscopically treated (0.0005%). Interestingly, the mean age of women with leiomyosarcomas was 61.2 ± 12.3 years old and no case of leiomyosarcomawas reported in reproductive age women (Lieng et al., 2015) .
Owing to the rare incidence of uterine sarcomas, there are neither published results from prospective trials identifying the risk factors for uterine sarcoma, nor safe diagnostic algorithms for patients with presumed benign leiomyomas. So, the majority of the data are of low quality as they are collected from retrospective case series studies in order to address this issue. Recently, a web registry for myometrium disorders has been designed and will be operational soon (ClinicalTrials.gov: NCT02940041, October 2016).
Furthermore, uterine sarcomas as rare malignant tumors, represent fewer than 5% of all uterine corpus cancers and have an incidence of about 17.1 per million. The increasing incidence of uterine sarcomas reported in the SEER studies may reflect improved diagnosis, and perhaps a true increase in an ageing population (Brooks et al., 2004) . Although limited number of unsuspected uterine sarcomas cases have been reported even in reproductive age women, the median age at diagnosis is 60 years and the majority of them occur after menopause. However, the FDA warning clearly states that there were insufficient data to stratify by age. This gap of knowledge needed to be addressed especially for women of different reproductive age groups, who plan to undergo laparoscopic morcellation of unsuspected leiomyoma and wish to preserve and not compromise their fertility by hysterectomy or open laparotomic myomectomy. However, a recently published retrospective cohort of 2075 patients in combination with other studies including totally 10 120 patients, answered this question and quantified the risk by age stratification. The results of this study, showed that the risk of unexpected uterine sarcoma varies significantly across age groups. Uterine sarcoma is associated with increasing age and peaks sharply in the perimenopausal range. Specifically, the risk of unexpected uterine sarcoma ranges widely between age groups, from as high 1 in 100 patients aged 75-79 years to <1 in 500 for those aged < 30 years. These data provide sufficient evidence to use morcellation during laparoscopic myomectomies, since 45-50 years old is the average age of peri-menopause. (Brohl et al., 2015) Another cohort from 496 hospitals retrospectively analyzed the occurrence of occult uterine cancer in 3220 patients who underwent laparoscopic myomectomy with electric power morcellation. This study found that 0.43% had a pathologic pre-invasive or invasive pathologic finding and 0.09% suffered from uterine cancer. Stratification by age group, showed that the prevalence of uterine cancer in women who had power morcellation was 0% in those younger than 40 years and rose to 0.97% in those aged 50-59 years and to 0% in women 60 years or older. In a multivariable model examining factors associated with uterine cancer, age was the strongest risk factor (Wright et al., 2015) .
The potential drawback of tissue dissemination during morcellation, motivated researchers to design a new in-bag morcellation system with promising results in the future (Rimbach et al., 2016) .
The present retrospective study showed that among reproductive age patients with presumed benign leiomyomas, who wish to preserve their fertility, minimally invasive surgery, should be the surgical 'gold standard' and electric power morcellation, which is an integral part of this approach should not be abandoned. The clearly demonstrated advantages of endoscopic surgery, which include improved pain control, less de novo adhesion formation, decreased infection risk and faster surgical recovery should not be overlooked by the possibility of uterine sarcoma, which in any case is very low in women of reproductive age. Certainly, not only multivariate models to examine predictors of safe use of electric power morcellation are necessary, but, also, new surgical methods and devices should be developed, so that women with leiomyomas can still be offered laparoscopic surgery. *This number refers to the ultrasonograpic features observed in our material based on the eight ultrasonographic characteristics described by Exacoustos et al. (2007) . mf = mitotic figures; hpf = high power field; U/S= ultrasound.
